Hu­mi­ra and Ste­lara con­tin­ue to lead spe­cial­ty drug spend­ing, but new­er drugs like Keytru­da, Skyrizi are clos­ing in — re­port

Spend­ing on spe­cial­ty drugs con­tin­ues to grow, dri­ven most­ly by more peo­ple us­ing them, but al­so by in­creas­ing prices.

Spe­cial­ty drug spend­ing jumped 14.1% year over year with 9.9% at­trib­uted to the num­ber of claims, but the re­main­ing 3.9% at­trib­uted to in­creased costs per claim, ac­cord­ing to Phar­ma­ceu­ti­cal Strate­gies Group’s sev­enth an­nu­al Artemetrx State of Spe­cial­ty Spend and Trend re­port.

While the in­creas­es are still caused by more claims and more peo­ple us­ing spe­cial­ty drugs, the per­cent­age at­trib­uted to the cost of the drugs grew more year over year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER